These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 30160983)
1. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors. McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983 [TBL] [Abstract][Full Text] [Related]
2. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587 [No Abstract] [Full Text] [Related]
3. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511 [TBL] [Abstract][Full Text] [Related]
4. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Takumi K; Fukukura Y; Higashi M; Ideue J; Umanodan T; Hakamada H; Kanetsuki I; Yoshiura T Eur J Radiol; 2015 Aug; 84(8):1436-1443. PubMed ID: 26022520 [TBL] [Abstract][Full Text] [Related]
6. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094 [TBL] [Abstract][Full Text] [Related]
7. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943 [TBL] [Abstract][Full Text] [Related]
8. Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. Canellas R; Burk KS; Parakh A; Sahani DV AJR Am J Roentgenol; 2018 Feb; 210(2):341-346. PubMed ID: 29140113 [TBL] [Abstract][Full Text] [Related]
9. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors. Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669 [TBL] [Abstract][Full Text] [Related]
10. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911 [TBL] [Abstract][Full Text] [Related]
11. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. Dogeas E; Karagkounis G; Heaphy CM; Hirose K; Pawlik TM; Wolfgang CL; Meeker A; Hruban RH; Cameron JL; Choti MA J Am Coll Surg; 2014 Apr; 218(4):628-35. PubMed ID: 24655849 [TBL] [Abstract][Full Text] [Related]
12. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs). Heaphy CM; Singhi AD Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689 [TBL] [Abstract][Full Text] [Related]
13. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867 [TBL] [Abstract][Full Text] [Related]
14. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794 [TBL] [Abstract][Full Text] [Related]
15. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919 [TBL] [Abstract][Full Text] [Related]
16. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort. Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341 [TBL] [Abstract][Full Text] [Related]
17. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Pea A; Yu J; Marchionni L; Noe M; Luchini C; Pulvirenti A; de Wilde RF; Brosens LA; Rezaee N; Javed A; Chianchiano P; Gobbo S; Regi P; Salvia R; Bassi C; He J; Weiss MJ; Cameron JL; Offerhaus GJA; Hruban RH; Lawlor RT; Scarpa A; Heaphy CM; Wood LD; Wolfgang CL Ann Surg; 2020 Mar; 271(3):566-573. PubMed ID: 30339629 [TBL] [Abstract][Full Text] [Related]
18. Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor. Choi SH; Kim HJ; Kim SY; Byun JH; Kim KW; Song KB; Kim SC; Kim MH Pancreas; 2017 Sep; 46(8):1056-1063. PubMed ID: 28787330 [TBL] [Abstract][Full Text] [Related]
19. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770 [TBL] [Abstract][Full Text] [Related]
20. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors. Kim HS; Lee HS; Nam KH; Choi J; Kim WH Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]